港股医疗板块再度走强，恒生医疗ETF(513060)涨超1.5%冲击3连涨，医药板块重估机会备受关注

Core Viewpoint - The healthcare sector, particularly the Hang Seng Healthcare Index (HSHCI), is experiencing a positive trend with significant stock price increases and a favorable outlook for valuation recovery due to policy improvements and ongoing innovation in drug development [3][4]. Group 1: Market Performance - As of July 30, 2025, the HSHCI rose by 0.75%, with notable increases in stocks such as BGI Genomics (4.02%) and MicroPort Medical (3.85%) [3]. - The Hang Seng Healthcare ETF (513060) has seen a 1.57% increase, marking its third consecutive rise, with a latest price of 0.71 HKD [3]. - Over the past week, the Hang Seng Healthcare ETF has accumulated an 8.71% increase, ranking in the top third among comparable funds [3]. Group 2: Fund Performance and Metrics - The Hang Seng Healthcare ETF has experienced a significant growth in scale, with a 1.70 billion HKD increase over the past week, placing it in the top third among comparable funds [4]. - The ETF's financing buy-in amount reached 2.45 billion HKD, with a financing balance of 2.37 billion HKD [4]. - Since its inception, the ETF has achieved a net value increase of 33.35% over the past two years, with a maximum monthly return of 28.34% and an average monthly return of 6.82% [4]. Group 3: Risk and Valuation Metrics - The ETF's Sharpe ratio for the past year stands at 2.30, indicating strong risk-adjusted returns [5]. - The ETF has the lowest relative drawdown among comparable funds, with a drawdown of 0.54% year-to-date [5]. - The latest price-to-earnings ratio (PE-TTM) for the HSHCI is 32.93, which is below 81.37% of the historical data over the past three years, indicating a low valuation [5]. Group 4: Top Holdings - The top ten weighted stocks in the HSHCI account for 61.7% of the index, including companies like BeiGene (61.60) and Innovent Biologics (18.01) [6].